Insmed EPS (Diluted) increased by 51.0% to $-0.76 in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 46.5%, from $-1.42 to $-0.76. Over 4 years (FY 2021 to FY 2025), EPS (Diluted) shows a downward trend with a 13.4% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Higher values indicate stronger profitability even when accounting for potential share dilution.
Calculated by dividing net income by the weighted-average number of common shares outstanding, assuming the conversion o...
Used by all public companies to provide a realistic view of earnings per share for investors.
eps_diluted| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$1.07 | -$0.96 | -$0.96 | -$0.80 | -$0.80 | -$1.09 | -$1.22 | -$1.17 | -$1.78 | -$1.11 | -$1.28 | -$1.06 | -$1.94 | -$1.27 | -$1.30 | -$1.42 | -$1.70 | -$1.75 | -$1.55 | -$0.76 |
| QoQ Change | — | +10.3% | +0.0% | +16.7% | +0.0% | -36.3% | -11.9% | +4.1% | -52.1% | +37.6% | -15.3% | +17.2% | -83.0% | +34.5% | -2.4% | -9.2% | -19.7% | -2.9% | +11.4% | +51.0% |
| YoY Change | — | — | — | — | +25.2% | -13.5% | -27.1% | -46.2% | -122.5% | -1.8% | -4.9% | +9.4% | -9.0% | -14.4% | -1.6% | -34.0% | +12.4% | -37.8% | -19.2% | +46.5% |